SG10201606872TA - Anti-tie2 antibodies and uses thereof - Google Patents

Anti-tie2 antibodies and uses thereof

Info

Publication number
SG10201606872TA
SG10201606872TA SG10201606872TA SG10201606872TA SG10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA SG 10201606872T A SG10201606872T A SG 10201606872TA
Authority
SG
Singapore
Prior art keywords
tie2 antibodies
tie2
antibodies
Prior art date
Application number
SG10201606872TA
Inventor
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201606872TA publication Critical patent/SG10201606872TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201606872TA 2011-08-19 2012-08-16 Anti-tie2 antibodies and uses thereof SG10201606872TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23

Publications (1)

Publication Number Publication Date
SG10201606872TA true SG10201606872TA (en) 2016-10-28

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201606872TA SG10201606872TA (en) 2011-08-19 2012-08-16 Anti-tie2 antibodies and uses thereof

Country Status (15)

Country Link
US (4) US9017670B2 (en)
EP (2) EP2744827B1 (en)
JP (2) JP6333174B2 (en)
KR (1) KR20140054303A (en)
CN (2) CN103874709B (en)
AR (1) AR087567A1 (en)
AU (1) AU2012299195B9 (en)
CA (1) CA2844306C (en)
ES (1) ES2694411T3 (en)
IL (1) IL230529A (en)
IN (1) IN2014CN02025A (en)
MX (1) MX359833B (en)
SG (1) SG10201606872TA (en)
UY (1) UY34271A (en)
WO (1) WO2013028442A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359833B (en) 2011-08-19 2018-10-12 Regeneron Pharma Anti-tie2 antibodies uses thereof.
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
PT3062811T (en) 2013-11-01 2019-06-11 Regeneron Pharma Angiopoietin-based interventions for treating cerebral malaria
KR102455680B1 (en) * 2014-07-15 2022-10-17 아스텔라스세이야쿠 가부시키가이샤 Novel anti-human tie-2 antibody
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3580568A1 (en) 2017-02-09 2019-12-18 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
KR102497171B1 (en) 2018-02-20 2023-02-08 기초과학연구원 Anti-angiopoietin-2 Antibodies and Uses Thereof
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
WO2019235856A1 (en) * 2018-06-07 2019-12-12 기초과학연구원 Antibody binding to tie2 and use thereof
CA3101506A1 (en) * 2018-06-07 2019-12-12 Institute For Basic Science Anti-tie2 antibodies and use thereof
JP2021529556A (en) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． Antitumor antagonist
JP2022540571A (en) 2019-06-28 2022-09-16 ゲンスン バイオファーマ、インコーポレーテッド An anti-tumor antagonist composed of a mutated TGFβ1-RII extracellular domain and an immunoglobulin scaffold
SG11202111656WA (en) * 2019-08-14 2021-11-29 Pharmabcine Inc Anti-tie2 antibody and use thereof
KR20220131894A (en) 2019-11-21 2022-09-29 유니티 바이오테크놀로지, 인크. Antibodies directed to TIE-2 and methods of use
AU2021242249A1 (en) 2020-03-24 2022-08-18 Genentech, Inc. Tie2-binding agents and methods of use
WO2022225182A1 (en) * 2021-04-23 2022-10-27 (주)니오테스바이오 Antibody specifically binding to angiopoietin-2, or fragment thereof
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
EP4463482A1 (en) * 2022-01-13 2024-11-20 Ingenia Therapeutics Inc. Vegf and tie2-binding fusion protein and uses thereof
CN115947818B (en) * 2022-10-25 2024-08-02 福州大学 Design of angiopoietin 1 mutant and its preparation method and application

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
AU4651893A (en) 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
WO1995013387A1 (en) 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tie-2, a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
NZ520171A (en) * 1999-12-20 2005-07-29 Immunex Corp Tweak receptor
RS50249B (en) 2000-06-23 2009-07-15 Bayer Schering Pharma Aktiengesellschaft, Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
BRPI0511065A (en) * 2004-06-04 2007-12-26 Pfizer Prod Inc method to treat abnormal cell growth
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
WO2006020706A2 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
EP1880993A4 (en) 2005-04-19 2009-12-30 Kyowa Hakko Kirin Co Ltd Nitrogen-containing heterocyclic compound
PT2076290T (en) 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
WO2010011242A2 (en) * 2008-03-24 2010-01-28 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnoisis of systemic anthrax infection
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
MX359833B (en) 2011-08-19 2018-10-12 Regeneron Pharma Anti-tie2 antibodies uses thereof.

Also Published As

Publication number Publication date
JP6333174B2 (en) 2018-05-30
US20130209492A1 (en) 2013-08-15
US20170088622A1 (en) 2017-03-30
IN2014CN02025A (en) 2015-05-29
EP2744827A1 (en) 2014-06-25
JP2014525934A (en) 2014-10-02
JP2017186347A (en) 2017-10-12
CN103874709B (en) 2016-12-21
IL230529A0 (en) 2014-03-31
ES2694411T3 (en) 2018-12-20
US20180291105A1 (en) 2018-10-11
EP2744827B1 (en) 2018-10-03
US9546218B2 (en) 2017-01-17
UY34271A (en) 2013-02-28
AU2012299195B9 (en) 2018-05-10
CA2844306A1 (en) 2013-02-28
JP6654165B2 (en) 2020-02-26
WO2013028442A1 (en) 2013-02-28
AU2012299195A1 (en) 2014-03-13
US10023641B2 (en) 2018-07-17
AR087567A1 (en) 2014-04-03
NZ621481A (en) 2016-04-29
MX2014001738A (en) 2014-03-27
US20150197578A1 (en) 2015-07-16
MX359833B (en) 2018-10-12
EP3415533A1 (en) 2018-12-19
CN103874709A (en) 2014-06-18
US10442864B2 (en) 2019-10-15
KR20140054303A (en) 2014-05-08
CA2844306C (en) 2022-08-16
AU2012299195B2 (en) 2018-04-19
CN106963946A (en) 2017-07-21
IL230529A (en) 2017-07-31
US9017670B2 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
IL288203B (en) Meditopes and meditope-binding antibodies and uses thereof
IL281250A (en) Anti-phf-tau antibodies and their uses
IL276573A (en) Anti-pd-l1 antibodies and uses thereof
IL259436A (en) Anti-angptl3 antibodies and uses thereof
IL230529A (en) Anti-tie2 antibodies and uses thereof
IL232399A0 (en) Anti-fgfr2 antibodies and uses thereof
EP2756094A4 (en) Anti-b7-h4 antibodies and their uses
DK2729170T3 (en) Antibody variants and uses thereof
EP2716359A4 (en) Complex and uses thereof
IL282122B1 (en) Antibody variants and uses thereof